Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Pay threat to EMIS users

The Medicines and Health Care Products Regulatory Agency is facing criticism from safety experts after admitting its drug regulatory role is entirely funded by pharmaceutical company levies.

On the opening day of the Commons health select committee inquiry into the influence of the pharmaceutical industry, MPs questioned whe- ther the funding was 'appropriate' given the MHRA's central role in providing drug warnings.

Professor Tony Avery, chair of the UK Drug Utilisation Research Group and a GP in Nottingham, said: 'It seems potentially problematic to have an organisation funded by a levy to the industry it is regulating.

'To convince the public of your independence it's not just about doing things correctly, it's about being seen to be doing them correctly as well.'

Professor Kent Woods, chief executive of the MHRA, defended his organisation, saying there were similar funding arrangements in the Netherlands and the US, and that he was 'quite comfortable' with fee income funding.

The inquiry will focus on how the industry affects drug innovation, regulatory control, efficacy, drug information, promotion and product evaluation.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say